BACKGROUND & AIMS: Although diabetes occurs frequently in pancreatic cancer, the value of new-onset diabetes as a marker of underlying pancreatic cancer is unknown. METHODS: We assembled a population-based cohort of 2122 Rochester, Minnesota, residents age > or =50 years who first met standardized criteria for diabetes between January 1, 1950, and December 31, 1994, and identified those who developed pancreatic cancer within 3 years of meeting criteria for diabetes. We compared observed rates of pancreatic cancer with expected rates based on the Iowa Surveillance Epidemiology and End Results registry. In a nested case control study, we compared body mass index (BMI) and smoking status in diabetes subjects with and without pancreatic cancer. RESULTS: Of 2122 diabetic subjects, 18 (0.85%) were diagnosed with pancreatic cancer within 3 years of meeting criteria for diabetes; 10 of 18 (56%) were diagnosed <6 months after first meeting criteria for diabetes, and 3 were resected. The observed-to-expected ratio of pancreatic cancer in the cohort was 7.94 (95% CI, 4.70-12.55). Compared with subjects without pancreatic cancer, diabetic subjects with pancreatic cancer were more likely to have met diabetes criteria after age 69 (OR = 4.52, 95% CI, 1.61-12.74) years but did not differ significantly with respect to BMI values (29.2 +/- 6.8 vs 26.5 +/- 5.0, respectively). A larger proportion of those who developed pancreatic cancer were ever smokers (92% vs 69%, respectively), but this did not reach statistical significance. CONCLUSIONS: Approximately 1% of diabetes subjects aged > or =50 years will be diagnosed with pancreatic cancer within 3 years of first meeting criteria for diabetes. The usefulness of new-onset diabetes as marker of early pancreatic cancer needs further evaluation.
BACKGROUND & AIMS: Although diabetes occurs frequently in pancreatic cancer, the value of new-onset diabetes as a marker of underlying pancreatic cancer is unknown. METHODS: We assembled a population-based cohort of 2122 Rochester, Minnesota, residents age > or =50 years who first met standardized criteria for diabetes between January 1, 1950, and December 31, 1994, and identified those who developed pancreatic cancer within 3 years of meeting criteria for diabetes. We compared observed rates of pancreatic cancer with expected rates based on the Iowa Surveillance Epidemiology and End Results registry. In a nested case control study, we compared body mass index (BMI) and smoking status in diabetes subjects with and without pancreatic cancer. RESULTS: Of 2122 diabetic subjects, 18 (0.85%) were diagnosed with pancreatic cancer within 3 years of meeting criteria for diabetes; 10 of 18 (56%) were diagnosed <6 months after first meeting criteria for diabetes, and 3 were resected. The observed-to-expected ratio of pancreatic cancer in the cohort was 7.94 (95% CI, 4.70-12.55). Compared with subjects without pancreatic cancer, diabetic subjects with pancreatic cancer were more likely to have met diabetes criteria after age 69 (OR = 4.52, 95% CI, 1.61-12.74) years but did not differ significantly with respect to BMI values (29.2 +/- 6.8 vs 26.5 +/- 5.0, respectively). A larger proportion of those who developed pancreatic cancer were ever smokers (92% vs 69%, respectively), but this did not reach statistical significance. CONCLUSIONS: Approximately 1% of diabetes subjects aged > or =50 years will be diagnosed with pancreatic cancer within 3 years of first meeting criteria for diabetes. The usefulness of new-onset diabetes as marker of early pancreatic cancer needs further evaluation.
Authors: Randal J Thomas; Pasquale J Palumbo; L Joseph Melton; Véronique L Roger; Jeanine Ransom; Peter C O'Brien; Cynthia L Leibson Journal: Arch Intern Med Date: 2003-02-24
Authors: Luigina Bonelli; Hugo Aste; Paolo Bovo; Giorgio Cavallini; Martina Felder; Riccardo Gusmaroli; Erminio Morandini; Paolo Ravelli; Romolo Briglia; Lucio Lombardo; Alberto De Micheli; Vittorio Pugliese Journal: Pancreas Date: 2003-08 Impact factor: 3.327
Authors: Sumana Gangi; J G Fletcher; Mark A Nathan; Jared A Christensen; William S Harmsen; Brian S Crownhart; Suresh T Chari Journal: AJR Am J Roentgenol Date: 2004-04 Impact factor: 3.959
Authors: Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff Journal: J Natl Compr Canc Netw Date: 2010-09 Impact factor: 11.908
Authors: Brian M Wolpin; Peter Kraft; Jihye Kim; Chen Yuan; Ana Babic; Ying Bao; Clary B Clish; Michael N Pollak; Laufey T Amundadottir; Alison P Klein; Rachael Z Stolzenberg-Solomon; Pari V Pandharipande; Lauren K Brais; Marisa W Welch; Kimmie Ng; Edward L Giovannucci; Howard D Sesso; JoAnn E Manson; Meir J Stampfer; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-22 Impact factor: 4.254
Authors: Manal M Hassan; Melissa L Bondy; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Peter W Pisters; Douglas B Evans; Rabia Khan; Ta-Hsu Chou; Renato Lenzi; Li Jiao; Donghui Li Journal: Am J Gastroenterol Date: 2007-08-31 Impact factor: 10.864
Authors: Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari Journal: Gastroenterology Date: 2018-04-30 Impact factor: 22.682